Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of QPX9003 in Healthy Adults
NCT04808414Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Modified Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Acinetobacter baumannii infection, Pseudomonas aeruginosa infection and Klebsiella pneumoniae infection comparing QPX9003 with Placebo (2 arms). Primary endpoints: Incidence of Treatment-Emergent Adverse events (AEs) up to 21 days, Number of patients with changes from baseline in safety parameters up to 13 days and 4 more. Started Jun 2021; status: completed.
02
Drugs
qpx9003
03
Conditions
Acinetobacter baumannii infectionPseudomonas aeruginosa infectionKlebsiella pneumoniae infection
Beyond the preview
Go deeper on NCT04808414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808414.